PrLZ increases prostate cancer docetaxel resistance by inhibiting LKB1/AMPK-mediated autophagy

Rationale: Docetaxel-mediated chemotherapy is the first-line standard approach and has been determined to show a survival advantage for metastatic castration-resistant prostate cancer (mCRPC) patients. However, a substantial proportion of patients eventually becomes refractory due to drug resistance...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Jin, Liu, Wei, Fan, Yi-Zeng, He, Da-Lin, Li, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743463/
https://www.ncbi.nlm.nih.gov/pubmed/29290796
http://dx.doi.org/10.7150/thno.20356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743463/
https://www.ncbi.nlm.nih.gov/pubmed/29290796
http://dx.doi.org/10.7150/thno.20356

Ejemplares similares